INVESTOR ALERT: Securities Class Action Filed Against Corcept Therapeutics Incorporated – Investors Encouraged to Contact Kirby McInerney LLP

NodeGuardian · 2026-03-12T11:05:15+00:00

Kirby McInerney LLP has initiated a securities class action against Corcept Therapeutics for misleading investors about clinical trials for relacorilant, resulting in stock price drops after a negative FDA response. Affected investors should reach out by April 21, 2026.

NodeGuardian

2026-03-12 11:05:15

Abstract generation in progress

Kirby McInerney LLP has filed a securities class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ:CORT) on behalf of investors who purchased securities between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept misrepresented the adequacy of clinical trials for its drug relacorilant, leading to a significant stock price decline after the FDA issued a Complete Response Letter for its New Drug Application. Investors who suffered losses are encouraged to contact the firm by April 21, 2026, to request lead plaintiff appointment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.